I-CARE
15.2.2024 14:31:33 CET | Business Wire | Press release
I-care, world leader in machine health, today presented the latest innovation in its Wi-care product range, the Wi-care 130 G23. This is the very first high-precision vibration sensor manufactured entirely in Belgium, capable of predicting more and more industrial breakdowns at an ever earlier stage. It is 100% autonomous, and therefore wireless, with a data flow that is 3 times more powerful and a battery life of 5 years. Thanks to this new technological innovation, I-care is strengthening AI-powered industrial maintenance 4.0. and enabling industries around the world to be more productive, safer and more sustainable.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240215735570/en/
Wi-care 130 G23 (Photo: I-care)
The Wi-care 130 G23, the very first sensor to be manufactured entirely in Belgium, is a revolution in the predictive maintenance business. It is an innovative tool capable of carrying out 3 types of measurement on machines simultaneously: vibration analysis, shock identification and temperature monitoring. It incorporates the state-of-the-art technologies, in particular piezoelectric sensors, and works on all types of industrial machine.
The Wi-care 130 G23 is 100% autonomous, and therefore wireless. It has a battery that will last for more than 5 years of uninterrupted use, even when taking high-precision measurements that consume a lot of energy. The sensor is ATEX certified, with a data stream 3 times more powerful, offering high resolution and high frequency.
Like all products in the Wi-care range, this new sensor from I-care is fully integrated into the WaaS (Wi-care as a Service) ecosystem, an all-inclusive machine maintenance solution covering everything from hardware to support services via the iSee platform, including analysis and reporting. .
I-care is an expert in analysing machine vibrations to predict industrial failures months or even years before they occur. The Wi-care 130 G23 enables errors to be detected at an early stage, so that more and more industrial failures can be predicted earlier and earlier. In this way, I-care is delivering on its mission to "change the way the world works" by making industries around the world more efficient, safer and more environmentally friendly.
"With the Wi-care 130 G23, not only the design but also, and above all, the performance of Wi-care has been enormously improved. It's a real revolution, and 100% Belgian," says Fabrice Brion, CEO of I-care. "Above all, it's about enabling the industrial manufacturing companies to work better. At I-care, this is our way of contributing to a more efficient and sustainable economy.”
About I-care
The I-care Group is a world leader in machine health. Our mission is to change the way the world works. Our AI and data-driven solutions predict industrial failures months or even years before they occur. Thanks to I-care, machines around the world are safer, more productive and more sustainable. Founded in 2004 in Mons, Belgium, we employ over 800 people, with 36 offices in 16 countries (Asia-Pacific, EMEA and the US) and customers in over 55 countries.
Pictures Wi-care 130 G23
Please find the pictures of the Wi-care 130 G23 here.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240215735570/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corpay Cross-Border Named the Official FX Supplier of Toulouse Football Club23.4.2026 14:30:00 CEST | Press release
Providing access to currency risk management and cross-border payments solutions Corpay, Inc.*, (NYSE: CPAY) a global leader in corporate payments, is pleased to announce that Corpay’s Cross-Border business has entered into an agreement with Toulouse Football Club to become their Official Foreign Exchange (FX) Supplier. A partnership brought together by SPORTFIVE, an international sports marketing agency. Through this partnership, Corpay Cross-Border will deliver comprehensive FX risk management solutions to support Toulouse Football Club’s operations. In addition, its award-winning platform will enable the club to manage global payments seamlessly through a single point of access. “Corpay Cross-Border is proud to be named the Official FX Supplier of Toulouse Football Club,” said Brad Loder, Chief Marketing Officer, Corpay Cross-Border Solutions. “This partnership reinforces Corpay’s position as a leading provider of corporate payments and currency risk management solutions within prof
Philip Morris International Expands its Partnership with Ducati Corse as Decades-Long Partnership Races Forward with Purpose23.4.2026 14:00:00 CEST | Press release
ZYN branding to be present at select MotoGP races in the 2026 season and beyond Philip Morris International1 (NYSE: PM) today announced an expanded partnership with Ducati Corse for the 2026 season and beyond. This next chapter introduces a major development: the ZYN brand of nicotine pouches—the number one nicotine pouch brand globally2—will feature on Ducati Corse MotoGP liveries at select races throughout the seasons. Just as Ducati pushes the limits of performance, ZYN represents PMI’s commitment to delivering innovation, offering a product that delivers exceptional quality while being thoughtfully designed. This partnership allows ZYN to connect with adult consumers in a space they’re passionate about—and to do so in a way that’s authentic, respectful, and dynamic. Philip Morris International’s relationship with Ducati Corse began in 2003—the year Ducati arrived in MotoGP—ushering in a bold new era of ambition. Since then, the collaboration has evolved alongside both organizations
Vitrealab and poLight ASA Partner to Tackle Coherence Artifacts in Laser-LCoS AR Displays23.4.2026 14:00:00 CEST | Press release
Vitrealab GmbH and poLight ASA (OSE: PLT) today announced a collaboration to advance laser illumination architectures for LCoS-based augmented reality (AR) displays, with a focus on mitigating coherence-related image artifacts while preserving system efficiency and compactness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260423345474/en/ Vitrealab GmbH and poLight ASA (OSE: PLT) today announced a collaboration to advance laser illumination architectures for LCoS-based augmented reality (AR) displays, with a focus on mitigating coherence-related image artifacts while preserving system efficiency and compactness. Vitrealab’s Quantum Light Chip combined with poLight's TWedge® wobulation technology helps create a higher performing and more manufacturable AR system. Laser-based illumination offers clear system-level advantages for LCoS based AR light engines, including high optical efficiency due to intrinsic polarization, imp
GE HealthCare Announces First Patient Dosed in Phase 2/3 LUMINA Trial for Manganese-Based MRI Contrast Agent Under FDA Fast Track Designation, Further Advancing Its Innovation Pipeline of Novel Imaging Agents23.4.2026 13:29:00 CEST | Press release
Mangaciclanol, if approved, could transform contrast-enhanced MR imaging by offering an alternative to - or even replacing - gadolinium-based MRI agentsA manganese-based MRI contrast agent could address concerns with gadolinium-based contrast agents around retention in the body, security of supply, and the environment, with mangaciclanol’s clinical development under FDA Fast Track designationThe program demonstrates GE HealthCare’s commitment to advancing novel imaging agents to address unmet patient needs GE HealthCare (Nasdaq: GEHC) today announced the first patient has been dosed in the international, multi-center Phase 2/3 LUMINA clinical trial of its manganese-based magnetic resonance imaging (MRI) contrast agent, mangaciclanol, at Mayo Clinic in Rochester, Minnesota. Mangaciclanol, if approved, could offer an alternative to – or even replace – gadolinium-based MRI contrast agents, the current standard of care. The investigational agent has been granted Fast Track designation by t
Croma Pharma Launches AI-Driven Tech Venture to Revolutionize Aesthetic Medicine via Clinicore Platform23.4.2026 13:13:00 CEST | Press release
New structure to drive AI-powered innovation and international expansion Croma Pharma has launched a strategic joint venture to accelerate the development of Clinicore, its premium digital solution for aesthetic practices. This dedicated entity will focus on scaling the next generation of the platform while ensuring full continuity for existing users. Clinicore: Elevating Practice Excellence through AI Clinicore is a specialized SaaS (Software as a Service) solution designed to optimize the daily operations of aesthetic clinics. By automating patient management, scheduling, and administrative workflows, it enables healthcare professionals to focus entirely on patient care. A core element of the new strategy is a strong focus on Artificial Intelligence. Clinicore is evolving into a smart assistant, utilizing AI-driven features for automated treatment documentation, intelligent onboarding tools, and advanced process automation. This ensures that clinics can operate at maximum efficiency
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
